Peri-implantitis is diagnosed primarily on the basis of clinical and radiological assessment: evaluation of peri-implant tissues, bleeding on probing, probing depth, suppuration, implant mobility, and bone loss. Increasingly, however, the question arises whether in some patients it is worth looking more broadly — also at the systemic inflammatory response. Blood tests do not replace local diagnostics, but in the future they may become an important complement to risk assessment, disease monitoring, and a better understanding of why peri-implantitis progresses faster in some patients than in others.
Contemporary diagnostics of peri-implantitis are based primarily on what the clinician can assess directly around the implant. Clinical parameters such as bleeding on probing, pocket depth, suppuration, the condition of soft tissues, oral hygiene, prosthetic design, and the possibility of effective cleaning are all important. Radiological imaging also remains essential, as it allows the clinician to assess bone loss around the implant.
This diagnostic model is the foundation of everyday practice, and it is difficult to imagine that it could be replaced by a single laboratory result. Peri-implantitis is a disease of peri-implant tissues, so its diagnosis must be based on local assessment. At the same time, growing evidence suggests that the local inflammatory process around an implant may be linked to the patient’s systemic immune and inflammatory response. This opens an important question: can blood provide additional information about the biology of this disease?
This question becomes particularly relevant if we look at peri-implantitis not only as an infection around an implant, but as a multifactorial disease. Bacterial biofilm remains the main factor initiating inflammation, but the subsequent course of the disease depends on host response, systemic diseases, metabolism, immune susceptibility, smoking, history of periodontitis, and local implant-related conditions. In some patients, inflammation remains limited and responds well to treatment. In others, it leads to rapid bone loss, recurrence, and difficult therapeutic decisions.
In this context, blood tests could serve as an additional “window” into the systemic dimension of inflammation. The point is not to diagnose peri-implantitis on the basis of a blood count or CRP. Rather, the aim is to better understand whether a patient with peri-implantitis shows signs of increased inflammatory burden, altered immune response, or a biological profile that may favor disease progression.
The most intuitive group consists of classical, single inflammatory markers. These include CRP, leukocyte count, IL-6, TNF-α, and IL-1β. They are well known in medicine, relatively easy to interpret, and have long been used in the assessment of inflammation. In the context of peri-implantitis, they can be analyzed both as systemic markers measured in blood and as local mediators assessed in peri-implant crevicular fluid. PERI-EDU project materials list CRP, IL-6, TNF-α, IL-1β, and WBC as systemic single inflammatory markers, and IL-1β, IL-6, TNF-α, IL-8, and MMP-8 as local markers in peri-implant crevicular fluid.
Their advantage lies in their availability and biological clarity. CRP may indicate inflammatory activity, leukocytes are a basic component of the immune response, and pro-inflammatory cytokines show that the immune system is activated. IL-1β, IL-6, and TNF-α are particularly important because they participate in processes leading to osteoclast activation and bone resorption — one of the key mechanisms of tissue destruction around implants.
The problem is that single inflammatory markers are nonspecific. Elevated CRP, changes in leukocyte count, or increased cytokine levels do not automatically indicate peri-implantitis. They may result from infection elsewhere in the body, chronic disease, trauma, inflammatory stress, pharmacotherapy, autoimmune disease, obesity, metabolic disorders, or many other processes. Therefore, their value in peri-implantitis does not lie in straightforward disease recognition, but in the possibility of complementing the overall picture of the patient. Source materials clearly emphasize that single markers are easy to measure and sensitive in detecting inflammation, but have limited specificity and do not reflect the complex immunological balance.
This limited specificity is particularly important in chronic, low-grade inflammatory processes. Peri-implantitis does not always have to be associated with a strong, clearly detectable systemic reaction. A local destructive process may be taking place while standard laboratory markers remain only mildly altered or even within reference ranges. On the other hand, a patient with a systemic disease may have elevated inflammatory parameters regardless of implant status. Interpretation therefore requires considerable caution.
This is why increasing attention is being paid not only to single markers, but also to composite indices calculated from routine blood count parameters. These include NLR, the neutrophil-to-lymphocyte ratio; PLR, the platelet-to-lymphocyte ratio; MLR, the monocyte-to-lymphocyte ratio; as well as more complex indices such as SII, SIRI, and AISI/PIV. The rationale is straightforward: instead of looking at one parameter, these indices attempt to capture relationships between different elements of the inflammatory and immune response.
This approach may be particularly interesting in peri-implantitis. Neutrophils, monocytes, and platelets are associated with inflammation, innate immunity, vascular processes, and tissue damage. Lymphocytes, in turn, reflect the regulatory and adaptive component of the immune response. Combining these parameters into a single index may describe the overall immuno-inflammatory status of the body better than a single laboratory value. Project materials indicate that CBC-derived indices are inexpensive, available, reproducible, and suitable for monitoring, although their use in peri-implantitis remains an area requiring further research.
In practice, this means that blood tests may be considered as part of risk stratification. A patient with peri-implantitis, a history of periodontitis, diabetes, metabolic syndrome, or cardiovascular disease may have a different inflammatory profile than a generally healthy patient. If clinical and radiological data are supplemented with information from blood tests, it may in the future become easier to identify patients who require closer monitoring, more intensive supportive care, or more cautious treatment planning.
At this stage, however, conclusions should not be taken too far. Blood-based inflammatory indices have important limitations. They may change under the influence of infection, stress, medication, autoimmune diseases, cancer, and many other factors. There are also no clearly established cut-off values specific to peri-implantitis. Most available data are observational or cross-sectional, which makes it difficult to establish cause-and-effect relationships. Materials discussing the advantages and limitations of aggregated inflammatory indices emphasize the need for further validation, standardization, and cautious interpretation.
This reservation is particularly important from the perspective of the practicing clinician. A blood test cannot be treated as a diagnostic shortcut. A normal result does not exclude disease around an implant, and an elevated result does not confirm it on its own. Meaning emerges only from the combination of information: clinical examination, probing, bleeding on probing, pocket depth, radiological assessment of bone loss, history of periodontitis, systemic diseases, medication use, smoking, oral hygiene, prosthetic design, and, potentially, laboratory parameters.
This integration of data is one of the key directions of the PERI-EDU project. The project does not assume that local diagnostics can be replaced by blood testing. Rather, its aim is to examine whether combining classical clinical parameters with assessment of systemic inflammatory response may help us better understand the course of peri-implantitis. This is particularly relevant in cases where the clinical picture does not fully explain the speed of disease progression, or where the patient presents multiple coexisting risk factors.
For academic and clinical education, this represents an important shift in perspective. Students and clinicians should not learn peri-implantitis solely as a local complication assessed with a probe and a radiograph. They should understand that bone loss around an implant may involve complex mechanisms: biofilm, immune response, cytokines, chronic diseases, metabolism, tissue quality, prosthetic design, and possibly measurable features of systemic inflammatory response.
In clinical practice, the question of blood tests is therefore a question about the future of more personalized implant dentistry. Will we be able to better identify patients in whom local inflammation has greater destructive potential? Can hematological indices help monitor response to treatment? Will combining clinical, radiological, and laboratory data allow for more accurate prognosis? There are no simple answers yet, but these questions are important for the development of modern diagnostics.
Caution is just as important here as innovation. Too rapid an adoption of blood markers as ready diagnostic tools could lead to overinterpretation. Ignoring their potential, however, would also be problematic, as it would limit our view of peri-implantitis to the area immediately around the implant. The most reasonable approach lies between these extremes: blood tests may be a promising complement, but their value must always be assessed in the context of the full clinical picture.
Can a blood test help assess a patient with peri-implantitis? Today, the answer is: potentially yes, but not independently and not as a simple test for diagnosing the disease. Its value may lie in better describing the systemic inflammatory background, identifying patients who require closer attention, and understanding why similar local conditions may lead to different disease courses.
This is the direction of research pursued by PERI-EDU. The aim is not to move away from classical implant diagnostics, but to expand it. The implant, peri-implant tissues, and the patient do not function separately. If we want to better predict, monitor, and treat peri-implantitis, we need to learn how to combine local data with what the biology of the entire organism can tell us.